reports
Sernova Announces New Positive Data from Phase I/II Trial Regarding Is...
Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet transplantationHistological data confirmation of healthy beta, alpha and delta cells secreting insulin, glucagon, and somatostatin in all Cell Pouch ChambersSernova’s Cell Pouch safely contains its therapeutic cells and provides full retrievability using conventional instruments and methodsPathology confirmed no evidence of detrimental fibrotic tissue associa...
Sernova Corp. Announces Appointment of New Chief Executive Officer
Sernova Corp. Announces Appointment of New Chief Executive Officer LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. (“Sernova” or the “Company”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company’s new Chief Executive Officer. James Parsons, on behalf of the Board of Directors of Sernova, stated, ...
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations f...
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte Orientale LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for th...
Sernova Announces New Advancements of Conformal Coating Technology in ...
Sernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced an update on its conformal coating immune protection technology program, that is used in combination with the Cell Pouch™. The goal of the program is to eliminate the need for chronic immunosuppression medications, currently used in isl...
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for...
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress All six patients in the first cohort (Cohort A) were successfully implanted with the 8-channel Cell Pouch System with post-transplant follow-up periods ranging from 6 months to 3.5 years;5 of 6 patients in Cohort A discontinued insulin therapy (insulin independent) following islet transplantation into the Cell Pouch and modest islet top-up via portal vein. All 6 patients achieved HbA1c values in the non-diabetic range (
Sernova to Provide Two Program Updates in Podium Presentations at 2023...
Sernova to Provide Two Program Updates in Podium Presentations at 2023 IPITA Congress Dr. Piotr Witkowski presenting new data from ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D) Dr. Alice Tomei presenting preclinical data on transplantation of conformal coated islet cells in pre-vascularized Cell Pouch LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced two oral presentations at the up...
EQS-News: Sernova-Telefonkonferenz für Investoren, die ursprünglich fü...
Emittent / Herausgeber: Sernova Corp. / Schlagwort(e): Konferenz/Sonstiges Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben 14.09.2023 / 22:06 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. LONDON, ONTARIO und WINDHAM COUNTY, CONNECTICUT, den 14. September 2023 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FWB/XETRA:PSH), ein Unternehmen im klinischen Stadium und Marktführer für Zelltherapeutika, gab heute bekannt, dass die ursprünglich für den 15. Septe...
EQS-News: Sernova Investor Conference Call Previously Scheduled for Se...
Issuer: Sernova Corp. / Key word(s): Conference/Miscellaneous Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22 14.09.2023 / 22:06 CET/CEST The issuer is solely responsible for the content of this announcement. LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 14, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m. Eastern...
Sernova Investor Conference Call Previously Scheduled for September 15...
Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22 LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m. Eastern Time. The call will now occur on September 22 at 10 a.m. Eastern Time. The business strategy and update call remains as scheduled for October 5, 2023. This call will ...
EQS-News: Sernova veranstaltet Telefonkonferenzen für Investoren zur V...
Emittent / Herausgeber: Sernova Corp. / Schlagwort(e): Konferenz/Sonstiges Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung 13.09.2023 / 13:01 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. - Vorstellung der neuen CEO Cynthia Pussinen und des kürzlich ernannten Chief Business Officer, Dr. Modestus Obochi, am 15. September 2023 - Telefonkonferenz zu Geschäftsentwicklung, Strategie und Ausblick am 5. Oktober 2023 LONDON, ONTARIO und...
EQS-News: Sernova to Host Investor Calls to Introduce Newly Appointed ...
Issuer: Sernova Corp. / Key word(s): Conference/Miscellaneous Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update 13.09.2023 / 13:01 CET/CEST The issuer is solely responsible for the content of this announcement. - Introduction of New CEO Cynthia Pussinen and Recently Appointed Chief Business Officer, Dr. Modestus Obochi, on September 15, 2023 - - Business Update, Strategy & Outlook Call on October 5, 2023 - LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 13, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a...
Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Pr...
Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update - Introduction of New CEO Cynthia Pussinen and Recently Appointed Chief Business Officer, Dr. Modestus Obochi, on September 15, 2023 - - Business Update, Strategy & Outlook Call on October 5, 2023 - LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will host two investor and analyst conference calls, with corresponding live webcasts. ...
Sernova Provides Development Update on Proprietary Cellular Conformal ...
Sernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device Dr. Alice Tomei of the University of Miami, Miller School of Medicine, to present updates in podium presentation at the 2023 IPITA-IXA-CTRMS Joint Congress being held in San Diego from October 26-29 LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today provided a development update on its exclusively licensed, proprietary...
Sernova Corporation Announces the Appointment of Cynthia Pussinen as C...
Sernova Corporation Announces the Appointment of Cynthia Pussinen as CEO Industry veteran with deep commercial experience joins to lead the next stage of growth and development Dr. Philip Toleikis will serve as Chief Technology Officer Sernova to host investor calls LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that its Board of Directors has appointed Cynthia Pussinen as Chief Executive Officer and a member of the Board of Di...
Sernova Expands Leadership Team with Appointment of Modestus Obochi, P...
Sernova Expands Leadership Team with Appointment of Modestus Obochi, Ph.D., MBA, as Chief Business Officer LONDON, Ontario, July 26, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the appointment of Modestus Obochi, Ph.D., MBA, a veteran dealmaker and strategic leader with 25+ years of biotech and pharmaceutical industry experience, as Chief Business Officer effective September 8, 2023. “Dr. Obochi brings additional invaluable industry acumen to our expanding leadership team,” sa...
Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data for...
Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™ at American Diabetes Association 83rd Scientific Sessions In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined islet transplants achieved insulin-independence for ongoing periods of 6 to 38 months.Following islet transplants to the 8-channel Cell Pouches, patients in the first cohort required only modest islet top-up via portal vein to achieve insulin independence, supporting the contribution to blood glucose control from islet grafts in the...
Sernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pou...
Sernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessions Company to host in-person only analyst and investor event at an offsite location following the presentation on Saturday, June 24 at the ADA Scientific Sessions LONDON, Ontario, June 22, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, will be presenting updated interim data from its ongoing Phase 1/2 clinical trial of the Cell Pouch Sy...
Sernova to Participate in Upcoming Truist Securities Cell Therapy Symp...
Sernova to Participate in Upcoming Truist Securities Cell Therapy Symposium LONDON, Ontario, June 16, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming symposia-cel Truist Securities Cell Therapy Symposium being held June 27, 2023 in New York City. Company management will also be participating in one-on-one investor meetings at the conference. symposia-cel - A Truist Securities Cell Therapy Symposium Format:Fireside ChatDate:June 27, 2023, 2:15p...
Sernova Announces Executive Alignment and Appoints New Board Chair
Sernova Announces Executive Alignment and Appoints New Board Chair LONDON, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the outcomes from a strategic and executive leadership review conducted by its Board of Directors (the “Board”). Following the recent 2023 Annual General Meeting of Shareholders (the “AGM”), the Sernova Board welcomed Mr. Brett Whalen, Dr. Steven Sangha and Mr. Bertram von Plettenberg as newly elected Directors. The newly constituted Board has...
EQS-News: Sernova Announces Research Collaboration with AstraZeneca to...
Issuer: Sernova Corp. / Key word(s): Alliance/Strategic Company Decision Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications 03.05.2023 / 13:01 CET/CEST The issuer is solely responsible for the content of this announcement. LONDON, Ontario – May 3, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s C...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.